Core Insights - The core viewpoint of the articles emphasizes the importance of domestic production of MRI equipment, particularly focusing on the self-sufficiency of key components like superconducting magnets and permanent magnets, which are crucial for overcoming industry bottlenecks [1][4]. Company Overview - Jianxin Superconducting has achieved significant technological breakthroughs and large-scale manufacturing in core components such as superconducting magnets and permanent magnets, becoming one of the earliest manufacturers in China to produce high-field superconducting magnets on a large scale and the largest global supplier of MRI equipment permanent magnets [1][4]. - The company has developed a diverse product matrix that includes 1.5T zero-evaporation superconducting magnets, 1.5T liquid helium-free superconducting magnets, and 3.0T zero-evaporation superconducting magnets [4]. Market Position and Strategy - The company aims to make MRI scans more affordable, reducing costs from thousands of yuan to hundreds, and has integrated these services into medical insurance, thereby enhancing access to quality healthcare [1][3]. - Jianxin Superconducting has established deep collaborations with leading manufacturers like Wandong Medical and Shenzhen Anke, ensuring stable supply of 1.5T products and gradually increasing supply of 3.0T products to rural hospitals [6]. Technological Innovation - The company has mastered 13 core technologies with independent intellectual property rights, covering areas such as electromagnetic fields, cryogenics, finite element analysis, structural design, intelligent control, and large-scale manufacturing processes [4]. - Jianxin Superconducting has successfully developed the world's first 1.5T liquid helium-free superconducting magnet, which does not require liquid helium and can automatically recover after quenching, making it suitable for emerging markets with limited maintenance capabilities [6][7]. Global Expansion - The company is actively expanding its overseas market presence, with over 50% of its MRI equipment products sold internationally. It has established local service networks in regions like India and Italy to address the affordability and usability issues in international markets [6][7]. - Jianxin Superconducting's global layout and technological innovations are expected to significantly reduce the overseas delivery and maintenance costs of superconducting magnets, thereby supporting leading manufacturers in promoting their products globally [7]. Long-term Vision - The company emphasizes a long-term commitment to technological innovation and market needs, focusing on core business areas while exploring the feasibility of applying superconducting technology in industrial sectors like wind power and power transmission [9]. - Jianxin Superconducting plans to invest in projects aimed at producing 600 sets of liquid helium-free superconducting magnets annually and upgrading high-field superconducting magnet production, reinforcing its commitment to sustainable growth and innovation in the healthcare sector [9].

12月24日，健信超导登陆上海证券交易所科创板，发行价18.58元/股，开盘价65.03元/股。截至13:59，健信超导股 价报65.73元/股，涨幅达253.77%。 "公司上市既是荣誉，更是责任。资本市场为健信超导提供了更广阔的发展平台，也对公司治理提出了严格要求。 我们将以更高标准强化公司治理，切实维护投资者的长期利益。"健信超导董事长许建益在上市仪式现场说。 许建益表示，上市后，健信超导将坚持以"设计并生产先进的MRI（医用磁共振成像）核心部件和推动磁共振行业 发展"为己任，通过掌握核心技术并持续创新，让磁共振成为大众用得起的日常诊查手段。 同时，健信超导将进一步拓展超导技术的应用范围，让超导技术更好地服务新能源、交通等更广阔的工业领域， 为超导技术的产业化做出更大贡献。 在上海证券交易所上市仪式现场，上海证券交易所副理事长霍瑞戎与健信超导董事长许建益签署证券上市协议。 广发证券副总经理、投行业务管理委员会主任委员胡金泉在上市仪式上表示，健信超导登陆科创板，是企业扎根 行业、厚积薄发的里程碑式跨越，为国内资本市场注入了兼具技术硬实力与成长潜力的优质标的。 "我们相信健信超导将以资本市场为新起点，勇立技 ...

"硬科技企业的核心竞争力源于自主研发，健信超导始终坚持'聚焦主业，技术创新'的核心方向。"许建 益表示，基于这一理念，公司对并购重组的态度审慎。短期内，公司将集中资源投入核心技术迭代与产 能扩张，通过内生增长筑牢发展根基。 从具体落地动作来看，健信超导本次募集资金将投向年产600套 无液氦超导磁体项目、年产600套高场强医用超导磁体技改项目，以及新型超导磁体研发项目。 "进入 资本市场后，企业的责任更重、压力更大，但我们绝不会浮躁。"许建益表示，未来健信超导仍将稳扎 稳打，以技术创新为核心驱动力，以市场需求为导向，在医疗健康领域持续赋能民生，在工业领域深挖 超导技术价值，走出一条硬科技企业的高质量发展之路。 "硬科技创业既是技术战，也是持久战。唯有以初心为舵、以坚韧为帆、以格局为岸，才能穿越行业周 期，实现技术报国的梦想。"健信超导董事长许建益表示，"进入资本市场后，企业的责任更重、压力更 大，但我们绝不会浮躁。"未来公司仍将稳扎稳打，以技术创新为核心驱动力，以市场需求为导向，走 出一条硬科技企业的高质量发展之路 在医疗装备国产化浪潮下，MRI（医用磁共振成像）设备核心部 件的自主可控，已成为突破行业瓶颈的关 ...

Core Viewpoint - The company Jianxin Superconductor (688805.SH) has successfully launched on the STAR Market, focusing on the research, production, and sales of core components for medical MRI equipment, which constitute approximately 50% of the cost of MRI devices [1][4]. Group 1: Company Overview - Jianxin Superconductor was established on December 11, 2013, and is recognized as one of the earliest manufacturers in China to scale the production of high-field superconducting magnets [7]. - The company has developed a diverse product matrix, including 1.5T and 3.0T superconducting magnets, and is the largest independent supplier of superconducting magnets globally [7]. - Jianxin Superconductor has established strong partnerships with renowned MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, facilitating the global promotion of MRI devices [7]. Group 2: Financial Metrics - The IPO price was set at 18.58 CNY per share, with an institutional offering price of 18.89 CNY per share, resulting in a market capitalization of 3.115 billion CNY [4]. - The company’s earnings per share (EPS) is projected with a price-to-earnings (P/E) ratio of 61.97, compared to the industry average of 31.79 [4]. Group 3: Fundraising and Investment Plans - Jianxin Superconductor plans to invest raised funds in several projects, including a 600-unit production line for liquid helium-free superconducting magnets (2.75 billion CNY), a technical upgrade for high-field superconducting magnets (2.60 billion CNY), and the development of new superconducting magnets (2.40 billion CNY) [6]. Group 4: Market Risks - The company faces a high customer concentration risk, with the top five customers accounting for 73.75% to 83.43% of total revenue from 2022 to mid-2025, with Fujifilm being the largest customer [8].

Core Viewpoint - The company Jianxin Superconductor (688805.SH) is set to be available for subscription on the Sci-Tech Innovation Board, focusing on the research, production, and sales of core components for medical MRI equipment, which constitute approximately 50% of the cost of MRI devices [1][6]. Group 1: Company Overview - Jianxin Superconductor was established on December 11, 2013, and is one of the earliest manufacturers in China to produce high-field superconducting magnets on a large scale [6]. - The company has developed a diverse product matrix, including 1.5T zero-evaporation superconducting magnets and 3.0T zero-evaporation superconducting magnets, becoming the largest independent supplier of superconducting magnets globally [6]. - Jianxin Superconductor has established close partnerships with renowned MRI equipment manufacturers such as Fujifilm, GE Healthcare, and others, with over 50% of its products being sold to international markets [6]. Group 2: Financial Information - The initial offering price is set at 18.58 yuan per share, with an institutional quotation of 18.89 yuan per share, and the company's market capitalization is approximately 2.337 billion yuan [3]. - The company’s projected earnings per share (PE) ratio is 61.97, compared to the industry average of 31.79 [3]. - The company plans to invest approximately 2.75 billion yuan in a project to produce 600 sets of non-liquid helium superconducting magnets, which accounts for 35.48% of the total fundraising [5]. Group 3: Risks and Challenges - The company faces a high customer concentration risk, with the top five customers accounting for 73.75% to 83.43% of total revenue from 2022 to the first half of 2025, with Fujifilm being the largest customer [7]. - Although sales and gross profit from Fujifilm do not exceed 50%, any significant changes in the customer landscape or performance could adversely affect the company's profitability [7].

Core Viewpoint - The company Jianxin Superconductor (688805.SH) has initiated its subscription with an issue price of 18.58 yuan per share and a price-to-earnings ratio of 61.97 times, focusing on the research, production, and sales of core components for MRI equipment, which account for approximately 50% of the cost of MRI devices [1]. Group 1: Company Overview - The company specializes in the research, production, and sales of core components for medical MRI equipment, including superconducting magnets, permanent magnets, and gradient coils [1]. - The company has achieved breakthroughs in core technologies for superconducting magnets, permanent magnets, and gradient coils, ensuring the independence and controllability of core components in the domestic MRI industry [2]. Group 2: Product Development and Market Position - The company has developed a comprehensive product matrix in the superconducting field, including 1.5T and 3.0T zero-evaporation superconducting magnets, becoming the world's leading independent supplier of superconducting magnets [2]. - The company has closed a 20-year technology gap with international giants in zero-evaporation superconducting technology and has broken the long-standing monopoly of European, American, and Japanese manufacturers in the 1.5T product field since 2015 [2]. Group 3: Technological Advancements - The company has transitioned from a follower to a leader in the next-generation helium-free superconducting technology, achieving a fully helium-free superconducting magnet and being recognized as the "international first set of equipment" by the Zhejiang Provincial Economic and Information Technology Department in 2021 [3]. - The company is the largest supplier of MRI permanent magnets globally, providing high-quality products that are economically viable and suitable for grassroots medical systems [3]. Group 4: Financial Performance - The company reported revenues of approximately 359 million yuan, 451 million yuan, 425 million yuan, and 252 million yuan for the years 2022, 2023, 2024, and the first half of 2025, respectively, with net profits of 34.63 million yuan, 48.73 million yuan, 55.78 million yuan, and 31.92 million yuan during the same periods [4]. - As of June 30, 2025, the total assets of the company were approximately 688.99 million yuan, with a debt-to-asset ratio of 29.22% [5].

健信超导扎根医用磁共振成像设备核心部件行业多年，形成了包括1.5T、3.0T及开放式零挥发超导磁体 和1.5T无液氦超导磁体在内丰富的产品矩阵，已成为全球排名第一的超导磁体独立供应商。 尊敬的各位嘉宾、各位投资者朋友： 大家好！ 非常感谢各位参加宁波健信超导科技股份有限公司首次公开发行股票并在上交所科创板上市网上投资者 交流活动。在此，我谨代表广发证券，向大家表示热烈的欢迎及衷心的感谢！ 作为健信超导本次发行上市的保荐人及主承销商，广发证券在与公司长期合作进程中，既见证其稳健快 速发展，亦深切体会到公司管理层具备的超前行业洞察力与深厚的从业经验。我们相信，以本次发行上 市为重要契机，健信超导必将在为国内企业提供更多超导技术国产方案的同时，努力开拓全球市场，开 启高质量发展新篇章。 在今天的网上交流中，我们将认真负责地回答各位投资者和各位朋友提出的问题，让大家能更全面、深 入地了解健信超导，把握投资机会，共享健信超导发展的硕果。欢迎大家踊跃提问，积极参与申购。 最后，预祝健信超导首次公开发行A股圆满成功！谢谢大家！ （文章来源：上海证券报） 在零挥发超导技术领域，公司追平了与国际巨头约20年的技术差距，并通过设 ...

Core Insights - The company, Ningbo Jianxin Superconductor Technology Co., Ltd., aims to make MRI technology accessible to the general public, focusing on superconducting magnets, permanent magnets, and gradient coils [2] - The company has made significant technological advancements, closing a 20-year gap with international competitors in zero-evaporation superconducting technology and breaking the monopoly of European, American, and Japanese manufacturers [2] - The company has developed a 1.5T helium-free superconducting magnet using all-solid-state conduction cooling technology, achieving international leadership in core parameters, performance indicators, and product costs [2] Market Position - The company is recognized as the world's leading independent supplier of superconducting magnets in the MRI industry, with a projected market share ranking of fifth globally for superconducting magnets in 2024 and first for permanent magnet products [3] - The company's products are increasingly integrated into the supply chains of major equipment manufacturers [3] Future Strategy - The company plans to implement a globalization strategy, enhancing independent innovation through technological iterations to lead the development of core components in the MRI industry [3] - The company aims to expand the application boundaries of superconducting core technologies in collaboration with customers, aspiring to become a leading brand in the global MRI core component industry [3]

Group 1 - The core point of the article is the approval by the China Securities Regulatory Commission for Ningbo Jianxin Superconducting Technology Co., Ltd. to conduct its initial public offering (IPO) on the Shanghai Stock Exchange, with a fundraising target of 865 million yuan [1] - Jianxin Superconducting primarily engages in the research, production, and sales of core components for medical magnetic resonance imaging (MRI) equipment, including superconducting magnets, permanent magnets, and gradient coils [1] - The company has developed a diverse product matrix in the superconducting field, including 1.5T zero-evaporation superconducting magnets, 1.5T liquid helium-free superconducting magnets, 3.0T zero-evaporation superconducting magnets, and open zero-evaporation superconducting magnets, making it the leading independent supplier of superconducting magnets in the global MRI industry [1]

Core Viewpoint - Ningbo Jianxin Superconductor Technology Co., Ltd. has successfully passed the IPO review for the Sci-Tech Innovation Board, positioning itself as the world's largest independent supplier of superconducting magnets for MRI equipment [1][2] Group 1: Company Overview - Jianxin Superconductor's IPO application was approved on October 21, with its review status updated to "submitted for registration" [1] - The company ranks fifth globally and second domestically in terms of market share for superconducting magnets used in MRI equipment, based on installed capacity [1] Group 2: Market Position and Technology - The company has closed a 20-year technology gap with international giants in the field of zero-evaporation superconducting technology, enhancing product performance and cost competitiveness through design and process innovation [2] - Jianxin Superconductor is one of the earliest manufacturers in China to scale up the production of high-field superconducting magnets, breaking the long-standing monopoly of European and Japanese manufacturers since 2015 [2] Group 3: Financial Performance - The company's revenue for the years 2022 to 2024 and the first half of 2025 is as follows: - 2022: 35.89 million yuan - 2023: 45.06 million yuan - 2024: 42.55 million yuan - 2025 (first half): 25.21 million yuan [2] - Net profit figures for the same periods are: - 2022: 3.46 million yuan - 2023: 4.87 million yuan - 2024: 5.58 million yuan - 2025 (first half): 3.19 million yuan [2] Group 4: Partnerships and Industry Impact - The company has established close partnerships with well-known MRI equipment manufacturers, including Fujifilm, GE Healthcare, and United Imaging Healthcare, contributing to the domestic MRI industry's core component supply [2]